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Abstract: Alpha-1-antitrypsin is the most abundant circulating protease inhibitor. It is mainly 
produced by the liver and secreted into the circulation where it acts to prevent excessive 
  proteolytic damage in the lungs by the enzyme neutrophil elastase. The most common severe 
deficiency allele is the Z mutation, which causes the protein to self-associate into ordered 
polymers. These polymers accumulate within hepatocytes to cause liver damage. The resulting 
lack of circulating α1-antitrypsin predisposes the Z homozygote to proteolytic lung damage 
and emphysema. Other pathways may also contribute to the development of lung disease. 
In particular, polymers of Z α1-antitrypsin can form within the lung where they act as a pro-
inflammatory stimulus that may exacerbate protease-mediated lung damage. Researchers 
recognized in the 1980s that plasma α1-antitrypsin levels could be restored by intravenous 
infusions of purified human protein. Alpha-1-antitrypsin replacement therapy was introduced in 
1987 but subsequent clinical trials have produced conflicting results, and to date there remains 
no widely accepted clinical evidence of the efficacy of α1-antitrypsin replacement therapy. This 
review addresses our current understanding of disease pathogenesis in α1-antitrypsin deficiency 
and questions why this treatment in isolation may not be effective. In particular it discusses 
the possible role of α1-antitrypsin polymers in exacerbating intrapulmonary inflammation and 
attenuating the efficacy of α1-antitrypsin replacement therapy.
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Introduction
Alpha-1-antitrypsin deficiency was first described in 1963 by Laurell and Eriksson1 
who noted the absence of the α1 band on serum protein electrophoresis in 5 out of 
1500 samples. Three of these individuals had developed early onset emphysema. The 
association with liver disease was reported 6 years later by Sharp and colleagues2 and 
more recently α1-antitrypsin deficiency has been associated with the development of 
bronchiectasis,3 asthma,4 vasculitis,5 and panniculitis.6
Alpha-1-antitrypsin is a member of the serine protease inhibitor or serpin 
superfamily of proteins. It is secreted mainly by hepatocytes but also by lung and 
gut epithelial cells,7–9 neutrophils10 and alveolar macrophages,11 and is present in the 
plasma at a concentration of 1.5–3.5 g/L (when measured by an immunodiffusion 
method). Circulating plasma α1-antitrypsin is a 394-amino-acid, 52 kDa, acute-phase 
glycoprotein that acts to inhibit the proteolytic enzyme neutrophil elastase. This enzyme 
is released at sites of inflammation and, if unregulated, causes proteolytic damage to 
connective tissue. This is particularly important in the lung as it is persistently exposed 
to inhaled pro-inflammatory stimuli.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Most individuals carry the normal “M” allele of 
α1-antitrypsin. However more than 100 different alleles 
have been identified to date, of which over 30 affect either 
the amount or the function of the molecule in vivo. Most 
α1-antitrypsin variants are named according to their migration 
during isoelectric focusing, variants A–L running faster and 
N–Z slower than the normal “M” protein. The most common 
severe deficiency mutant is the “Z” (Glu342Lys) allele which 
is thought to have originated in northern Europe (where the 
prevalence is 2%–4%)12,13 and is also seen as the predominant 
severe mutation in North America, Australia, and New 
Zealand.14 Other important disease-causing alleles include 
Siiyama (Ser53Phe), prevalent in Japan,15 and Mmalton 
(∆52Phe) which is the most common rare deficiency allele 
seen in Sardinia16 and which has been reported sporadically 
in the UK and Canada. Table 1 details the characteristics of 
recognized deficiency and null17 alleles.
Individuals with abnormal alleles have a plasma deficiency 
due to a lack of secretion of α1-antitrypsin from hepatocytes.18 
The severity of the plasma deficiency is predictable with the 
S allele reducing plasma levels to 60% of normal and the 
Z allele to 10% of normal; thus an SZ compound heterozygote 
has plasma levels that are 40% of normal. The resulting lack 
of elastase inhibition contributes to tissue destruction and 
panlobular emphysema, particularly in the inflamed lungs 
of smokers who have a significantly reduced life expectancy 
when compared with never smokers.19 Indeed α1-antitrypsin 
deficiency is the only known genetic cause of emphysema 
and is found in 1%–2% of all cases of chronic obstructive 
pulmonary disease (COPD).20
Alpha-1-antitrypsin augmentation therapy was developed 
to replace the deficient circulating protein and so ameliorate 
the progression of the associated emphysema.21 It is now 
widely used in many countries for individuals with severe 
deficiency of circulating α1-antitrypsin. However no 
randomized controlled studies have convincingly shown it 
to be an effective strategy in slowing the progression of lung 
disease or reducing mortality.22 This may be due to a lack of 
suitably powered studies although the pathogenesis of this 
condition is complex which may mean that this approach has 
only limited efficacy. This review considers the factors that 
may mitigate against the complete or partial effectiveness 
of α1-antitrypsin augmentation therapy.
Pathogenesis of disease: α1-antitrypsin 
function, processing and polymerization
Normal “M” α1-antitrypsin is secreted from the liver and 
acts as a very effective protease inhibitor. It binds neutrophil 
elastase via a methionine residue at position 358, on the 
reactive center loop of the protein (Figure 1). After binding, 
the enzyme is translocated from one end of the protein to the 
other in association with insertion of the reactive loop into 
β-sheet A. This forms a covalently linked complex of enzyme 
and inhibitor that is cleared from the circulation.
The Z (Glu342 Lys), Siiyama, and probably many 
other alleles result in a delay in folding in the secretory 
pathway of hepatocytes.23,24 Much of the protein fails to 
fold and is “timed out” by the folding sensor manosidase 
I.25 This material is a substrate for endoplasmic reticulum 
(ER) associated degradation and is destroyed by the 
proteasome.26–28 A proportion is folded correctly, trafficked 
through the endoplasmic reticulum and Golgi apparatus and 
secreted into the circulation. The remainder is folded to a 
near-native conformation but does not achieve the native 
state. The Glu342 Lys mutation results in an expansion 
of β-sheet A and perturbation of the F helix to form an 
intermediate that we have termed (M*).29 The reactive center 
loop of a second α1-antitrypsin molecule can then bind to 
this intermediate, forming a dimer that extends to form a 
polymer.18 The resultant polymer has an ordered, repeating 
structure but no anti-neutrophil elastase activity, because the 
reactive loop that is central to the polymerization process is 
buried in β-sheet A of another molecule (Figure 1). These 
polymers are sequestered within the ER of hepatocytes 
where they form diastase resistant, periodic acid-Schiff stain 
positive inclusions, which are associated with liver disease 
(Figure 2).18 The Z α1-antitrypsin that is correctly folded 
and trafficked through the secretory pathways still has the 
propensity to form polymers. These have been identified in 
the lung30 and in biopsies from the skin31 and kidneys32 from 
Z α1-antitrypsin homozygotes.
Study of the consequences of abnormally folded pro-
tein accumulation in hepatocytes has helped shed light 
on the mechanism of this gain-of-function toxicity that 
causes α1-antitrypsin deficiency associated liver disease. 
The presence of polymers of α1-antitrypsin within the ER 
causes ER stress. This is defined as a state in which unfolded 
proteins accumulate and aggregate within the ER, perturb-
ing normal ER function. Misfolded protein accumulation 
triggers the unfolded protein response (UPR); resident ER 
chaperones involved in protein folding are upregulated 
and translation of the abnormal protein is downregulated 
to restore homeostasis.33 An excess of protein traffic, for 
example following viral infection of a cell, triggers the ER 
overload response (EOR), resulting in calcium-dependent 
NF-κB activation.34Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Pathogenic alleles that cause α1-antitrypsin deficiency
Variant Mutation Molecular basis of disease Clinical features Epidemiology
Deficiency alleles
i98 Arg39Cys Protein misfolding; able to form 
heteropolymers.  
Reduced serum protein
No clear disease association Disease only reported in  
compound heterozygotes
King’s99 Hisp334Asp Rapid polymerization in hepatocyte 
endoplasmic reticulum, delayed 
secretion
Neonatal jaundice.  
Presumed high risk of  
emphysema in homozygote/
compound heterozygote
Case report
Mheerlen100 Pro369Leu Retained in the endoplasmic  
reticulum, none secreted
High risk of emphysema  
in homozygotes/compound 
heterozygotes.  
Unknown liver disease risk
Case report
Mmalton101 ∆52Phe  
(M2 variant)
intracellular degradation and 
polymerization; low serum 
concentration
well established association  
with liver disease and  
emphysema in homozygotes
Most common rare  
deficiency allele in Sardinia;16  
seen sporadically in the UK  
and Canada
Mmineral  
springs102
Gly67Glu Abnormal post-translational 
biosynthesis but no polymerization; 
low serum concentration
emphysema in homozygotes Unusual as described in a  
Afro-Caribbean individual  
in the United States
Mnichinan103 ∆52Phe and Gly148  
Arg
intracellular polymerization in 
hepatocytes and plasma deficiency
Risk of liver disease and  
emphysema
Case report (Japanese family   
with consanguineous origin)
Mpalermo104 ∆51Phe Serum deficiency High risk of emphysema  
in homozygotes
Case report
Mprocida105 Leu41Pro Unstable protein structure leading 
to intracellular degradation; reduced 
catalytic activity of circulating protein
High risk of emphysema  
in homozygotes
Case report
Mvall d’hebron106 
(=Mwurzburg)100
Pro369Ser Retained in the endoplasmic  
reticulum, none secreted
Presumed risk of emphysema 
in homozygotes/compound 
heterozygotes; 50% normal  
serum α1-antitrypsin level  
in M/vall d’hebron (/wurzburg)  
heterozygotes
Case reports from Spain  
and Germany
Mvarallo107 ∆41–51, replaced with  
22 bp sequence  
creating stop codon  
at 70–71
Unknown intracellular defect Presumed risk of emphysema  
in homozygotes/compound  
heterozygotes; 50% normal  
serum α1-antitrypsin level  
in M/Mvarallo heterozygote
Case report
Pittsburgh108 Met358 Arg Function altered to an antithrombin Fatal bleeding disorder Case report
Plowell  
(=QO Cardiff)  
and Pduarte109–111
Asp256val  
(M1 and M4  
alleles respectively)
intracellular degradation and plasma 
deficiency
increased risk of emphysema  
in Z/QO compound  
heterozygotes
Case report
S Glu264val Protein misfolding and reduced 
secretion; able to form  
heteropolymers with Z α1-antitrypsin
Emphysema seen in SZ 
heterozygotes but less  
severe than in ZZ.112  
Cirrhosis reported in SZ 
heterozygotes113
Most common deficiency  
variant. Carrier frequency:  
1:5 Northern europe  
1:30 USA  
1:23 Australian Caucasian  
1:26 New Zealand Caucasian   
Rare/non-existent in Asia,  
Africa and Australian 
Aboriginals114
Siiyama115 Ser53Phe intracellular degradation and 
polymerization; low serum 
concentration
Liver disease and  
emphysema in homozygotes
Rare, but most common  
deficiency allele in Japan
wbethesda116 Ala336Thr intracellular degradation,  
serum levels 50% normal
Risk of liver disease  
and emphysema in  
compound heterozygotes
Case report
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Table 1 (Continued)
Variant Mutation Molecular basis of disease Clinical features Epidemiology
Ybarcelona117 Asp256val and  
Pro391His
Unknown intracellular defect;  
very low serum protein
Severe emphysema  
reported in homozygote
Case report
Z Glu342 Lys intracellular degradation and 
polymerization; low serum 
concentration
Homozygotes: well  
established association with  
liver disease and emphysema.  
MZ heterozygotes may be  
more susceptible to airflow 
obstruction118 and chronic  
liver disease119
Commonest severe 
deficiency variant. Carrier 
frequency:  
1:27 Northern europe  
1:83 USA  
1:75 Australian Caucasian  
1:46 New Zealand Caucasian   
Not seen in China, Japan,  
Korea, Malaysia, Northern  
and western Africa111
Zausburg  
(=Ztun)120,121
Glu342 Lys  
(M2 variant)
intracellular degradation and 
polymerization; low serum 
concentration
Liver disease and emphysema 
in homozygotes/compound 
heterozygotes
Case report
Zwrexham122 Ser−19 Leu and Glu342  
Lys (Z mutation)
Poor expression, low serum 
concentration
emphysema reported in  
compound Z/Zwrexham  
compound heterozygotes.  
Unclear whether Ser-19 Leu  
would cause disease in  
absence of Z mutation
Case report
Null (QO) alleles
QO Bellingham123 Lys217 stop codon No detectable α1-antitrypsin mRNA High risk of emphysema in  
homozygotes/compound  
heterozygotes
Case report
QO Bolton124 ∆1bpPro362  
causing stop codon  
at 373
Truncated protein; intracellular 
degradation and no secreted protein
High risk of emphysema in  
homozygotes/compound  
heterozygotes
Case report
QO Cairo125 Lys259 stop codon Unknown intracellular defect High risk of emphysema in  
homozygotes/compound 
heterozygotes
Case report
QO Clayton126 Pro362 insC  
causing stop codon  
at 376
Truncated protein; intracellular 
degradation and no secreted protein
High risk of emphysema in  
homozygotes/compound  
heterozygotes
Case report
QO Devon  
(=QO Newport)122
Gly115Ser and Glu342  
Lys (Z mutation)
intracellular degradation and 
polymerization; reduced serum 
concentration
Risk of emphysema and liver  
disease in compound  
heterozygotes.  
Unclear whether Gly115Ser  
would cause disease in  
absence of Z mutation
Case report
QO Granite  
Falls127
∆1bpTyr160  
causing stop codon
No detectable α1-antitrypsin mRNA Severe emphysema reported  
in Z compound heterozygote
Case report
QO Hong Kong128 ∆2bpLeu318  
causing stop codon  
at 334
Truncated protein; intracellular 
aggregation (no polymerization), 
degradation and no secreted protein
High risk of emphysema in 
homozygotes/compound 
heterozygotes
Case reports (individuals  
of Chinese descent)
QO isola  
di Procida129
∆17 Kb inc.  
exons ii–v
No detectable α1-antitrypsin mRNA emphysema reported in  
Mprocida compound  
heterozygote
Case report
QO Lisbon104 Thr68ile Truncated protein; not secreted High risk of emphysema  
in homozygotes. 50% normal  
serum α1-antitrypsin in M/QO  
Lisbon heterozygotes
Case report
QO  
Ludwisghafen130
ile92 Asn Disruption of tertiary structure; 
intracellular degradation and no 
detectable serum protein
High risk of emphysema in  
homozygotes/compound  
heterozygotes
Case report
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It is striking that polymers of α1-antitrypsin do not 
activate the UPR in the absence of a second “hit” such as 
heat or accumulation of other misfolded proteins; this is likely 
to be due to the ordered nature of the polymers.35 They do 
however activate the EOR.36,37 This results in inflammatory 
mediator production,38 relative resistance to cell death,36,39 
and an increase in cell proliferation. Though the precise 
mechanism by which this causes liver disease has not been 
elucidated, it follows that abnormal cell survival in the   setting 
of a pro-inflammatory environment may lead to both hepatitis 
and neoplasia.
Clinical features of α1-antitrypsin 
deficiency related liver disease
Intracellular polymers form inclusions that are associated 
with neonatal hepatitis, cirrhosis, and hepatocellular 
carcinoma.40,41 Cholestatic jaundice affects one in ten 
neonates with α1-antitrypsin deficiency, 15% of whom 
develop juvenile cirrhosis. Liver disease can also become 
clinically relevant later in life with almost 50% of patients 
over the age of 50 having histological features consistent with 
cirrhosis in an autopsy series.41 Vaccination against hepatitis 
A and B is recommended as viral hepatitis may predispose 
to development of chronic liver disease.42 It is recommended 
that alcohol consumption does not exceed 60 g/day but there 
is currently no proven association between alcohol excess and 
the development of liver disease in α1-antitrypsin deficiency.43 
Weight control is advisable in view of an association between 
obesity and cirrhosis in these individuals.44 Screening for 
cirrhosis and hepatocellular carcinoma (HCC) with liver 
ultrasound is warranted; some clinicians may choose to use 
serum alpha-fetoprotein as an additional screening tool for 
HCC. Treatment of hepatic failure follows that for any other 
condition; liver transplantation is an option and accounted 
for 1.1% of adult liver transplants in the US in the period 
1995–2004. Liver transplantation cures the circulating 
deficiency of α1-antitrypsin and 5-year survival rates are 
excellent at around 83%.45
Alpha-1-antitrypsin deficiency  
and lung disease
Alpha-1-antitrypsin deficiency is classically associated with 
early-onset, lower zone emphysema. Smoking individuals with 
severe circulating deficiency of α1-antitrypsin tend to develop 
clinical disease in the third or fourth decade with the most 
common reported symptoms being breathlessness, cough, and 
wheeze.46 Those with a smoking history develop more severe 
disease at an earlier age than could be explained by smoking 
alone. There is often a significant delay from symptom onset 
to diagnosis;47 a 2003 survey revealed a time lapse of more 
than 5 years between first symptom and diagnosis in a cohort 
of 1851 individuals with α1-antitrypsin deficiency.48 A chest 
radiograph typically shows hyperinflation and a paucity of 
vascular markings in the lower zone; pulmonary function test-
ing reveals evidence of airflow obstruction, gas trapping, and 
impaired gas transfer. The natural history of α1-antitrypsin 
deficiency-associated emphysema is highly variable but disease 
is often progressive, with faster lung function decline seen in 
ongoing smokers,49 those with recurrent exacerbations,50 and 
those with environmental dust exposure.51
Table 1 (Continued)
Variant Mutation Molecular basis of disease Clinical features Epidemiology
QO Mattawa  
(M1allele)131/QO  
Ourém (M3 allele)132
Leu353Phe  
causing stop codon  
at 376
Truncated protein; misfolding and 
reduced serum levels
emphysema reported in  
homozygotes
Case reports
QO Riedenburg133 whole gene  
deletion
No gene expression High risk of emphysema in  
homozygotes/compound 
heterozygotes
Case report
QO  
Saarbueken104
1158dupC  
causing stop codon  
at 376
Truncated protein; not secreted High risk of emphysema in 
homozygotes.  
50% normal serum  
α1-antitrypsin in M/QO  
Saarbueken heterozygotes
Case report
QO  
Trastevere134
Try194 stop codon Reduced mRNA, degradation of 
truncated protein; not secreted
emphysema reported in  
compound heterozygote
Case report
QO west135 ∆Gly164  
Lys191
Aberrant mRNA splicing,  
intracellular degradation and  
no detectable serum protein
emphysema reported in  
compound heterozygote
Case reportDrug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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It is apparent from the study of the rare null mutations 
of α1-antitrypsin that the lack of circulating protein (ie, 
loss-of-function) plays a vital role in the development of 
emphysema. Indeed, null α1-antitrypsin homozygotes have 
particularly severe disease.52 There is now increasing evi-
dence that α1-antitrypsin polymers are also important in the 
development of the panacinar emphysema that is classically 
seen in this condition. Alpha-1-antitrypsin enters the lung 
from the circulation by passive diffusion53 and is also 
  produced locally in alveolar macrophages and bronchial 
and alveolar epithelial cells.7,8,11 In individuals homozygous 
for the Z allele, all α1-antitrypsin has the propensity to form 
A
B D P
2
3
M M*
L
1
Z
Figure 1 (A) inhibition of neutrophil elastase by α1-antitrypsin. After docking (left) the neutrophil elastase (grey) is inactivated by movement from the upper to the lower 
pole of the protein (right). This is associated with insertion of the reactive loop (red) as an extra strand into β-sheet A (green). Reproduced from Lomas et al136 with 
permission. (B) The structure of α1-antitrypsin is centered on β-sheet A (green) and the mobile reactive center loop (red). Polymer formation results from the Z variant of 
α1-antitrypsin (Glu342 Lys at P17; arrowed) or mutations in the shutter domain (blue circle) that open β-sheet A to favor partial loop insertion (step 1) and the formation 
of an unstable intermediate (M*). The patent β-sheet A can either accept the loop of another molecule (step 2) to form a dimer (D), which then extends into polymers (P).   
A small proportion of the unstable serpin molecules can accept their own loop (step 3) to form an inactive, thermostable, latent conformation (L). The individual molecules 
of α1-antitrypsin within the polymer are colored red, yellow, and blue. 
Reproduced from Gooptu et al29 with permission.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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polymers regardless of its source. Indeed, polymers have been 
detected in bronchoalveolar lavage fluid54,55 and explanted 
lung sections from Z homozygotes, where they are seen 
both around capillaries (consistent with circulating poly-
mers) and epithelial cells (suggesting local synthesis). This 
local production of polymers is exacerbated by the presence 
of cigarette smoke.56 The most compelling evidence for 
  pulmonary α1-antitrypsin production of polymers comes 
from a bronchoalveolar lavage sample from an α1-antitrypsin 
ZZ homozygote following liver transplantation which con-
tained polymers; because wildtype M antitrypsin is produced 
from the transplanted liver this confirms that Z α1-antitrypsin 
is produced locally and then forms polymers.55
In stark contrast to the anti-inflammatory properties of 
monomeric M α1-antitrypsin, Z α1-antitrypsin polymers are 
pro-inflammatory, acting as neutrophil chemoattractants. 
Polymers, largely located in the interstitium, attract neutro-
phils as they migrate from capillary to alveolus in response 
to inflammatory mediators induced by cigarette smoke.56 
Here they cause neutrophil degranulation and release of 
elastases and other degradative enzymes.57 Additionally, the 
lungs of Z α1-antitrypsin homozygotes contain increased 
levels of chemotactic cytokines including interleukin-8 (IL-8) 
and leukotriene B4 (LTB4), compared with controls.58 This 
may be a response of alveolar macrophages to uninhibited 
neutrophil elastase59 but may also reflect stress signaling path-
ways, perhaps including the UPR, induced by intracellular 
polymers in epithelial cells and alveolar macrophages.
The pro-inflammatory environment in the lung is further 
amplified by a number of other mechanisms: (i) monomeric 
Z α1-antitrypsin is ten-fold less efficient than wild type 
protein at inhibiting neutrophil elastase,60 (ii) oxidation of 
α1-antitrypsin by superoxide radicals may not only reduce 
its efficacy further,61 it may also stimulate release of IL-8 and 
monocyte chemoattractant protein-1 from epithelial cells,62 
(iii) the reduction in intracellular α1-antitrypsin may lead 
to loss of inhibition of caspase-3, leading to uncontrolled 
cellular apoptosis.63 This is in contrast to the relative paucity 
of apoptosis seen in the liver and perhaps reflects the 
activation of the UPR in response to the second hit, which 
is the inflammatory milieu of the lung in Z α1-antitrypsin 
homozygotes.
Taken together, a model for the pathogenesis of lung 
disease can be proposed in the Z α1-antitrypsin homozygote 
involving both loss-of-function and gain-of-function 
components. The lack of functional α1-antitrypsin (due 
to reduced secretion, reduced antiprotease activity, 
and the polymerization of Z α1-antitrypsin) creates a 
pro-inflammatory and proteolytic environment. This is 
exacerbated by the presence of interstitial polymers and 
cytokines, both of which are chemotactic for neutrophils, 
and can be further driven by oxidation of α1-antitrypsin 
due to cigarette smoke. Finally, a lack of intracellular 
α1-antitrypsin prevents inhibition of apoptotic pathways.
The resulting inflammation, proteolysis, and cell death lead 
to the development of panacinar emphysema, the hallmark 
of α1-antitrypsin deficiency-related lung disease.
Systemic diseases associated  
with α1-antitrypsin deficiency
Alpha-1-antitrypsin deficiency is associated with other 
inflammatory conditions including panniculitis and 
anti-neutrophil cytoplasmic antibody (ANCA) positive 
vasculitis. The lesions of panniculitis contain neutrophils 
that co-localize with polymers, though normal skin of the 
Z α1-antitrypsin homozygote also contains polymers.31 
It remains to be seen whether polymers are simply an 
incidental finding, or whether they play a role in the pathogen-
esis of the disease. The repeated observation that intravenous 
A
B
Figure 2 (A) electron microscopy (×20,000) of a hepatocyte from a Z homozygote 
showing a massive inclusion (arrowed) in the endoplasmic reticulum. Reproduced 
from Lomas et al18 with permission. (B) The intra-hepatic polymers of mutant Z 
α1-antitrypsin have the appearance of beads on a string on electron microscopy. 
Reproduced from Lomas et al137 with permission.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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α1-antitrypsin replacement therapy can have an effect on flare 
frequency and severity of panniculitis64 points to loss-of-
function being of greater significance in this manifestation 
of disease.
Case–control studies have confirmed a link between Z 
α1-antitrypsin deficiency and ANCA-associated vasculi-
tis, and polymers can also be seen in the renal biopsies of 
affected individuals.32 In addition to the low absolute levels 
of circulating α1-antitrypsin, it is postulated that polymers 
may become trapped within glomeruli, promoting neutrophil 
degranulation and inflammation as they do within the inter-
stitium of the lung.32
Current treatment strategies
The management of patients with α1-antitrypsin deficiency 
related emphysema closely resembles that of patients with 
“usual” smoking related COPD. Smoking cessation is 
crucial to prevent progression of disease with the rate of 
forced expiratory volume in 1 second (FEV1) decline being 
significantly less in those who quit successfully.49 Other 
potentially preventative strategies include minimization of 
respiratory irritant exposure and pneumococcal and influenza 
vaccination.43 Inhaled corticosteroids are commonly used and 
theoretically should reduce neutrophilic airway inflammation; 
small studies have suggested a possible benefit in terms of lung 
function in some patients65,66 and inhaled   bronchodilators may 
result in symptomatic benefit despite little objective evidence 
of  a bronchodilator response. Oxygen used in accordance with 
national guidelines and pulmonary rehabilitation programs 
may also be useful.
Lung volume reduction surgery (LVRS) is uncommonly 
used in individuals with α1-antitrypsin deficiency. Individuals 
with emphysema of any cause with predominantly basal 
disease have a worse outcome than those with upper lobe 
disease.67 Alpha-1-antitrypsin deficient patients undergoing 
LVRS achieve initial improvements in FEV1 and exercise 
tolerance comparable with non-deficient patients but the 
benefits are shorter lived.68 It has been suggested that 
this is a consequence of disease distribution rather than 
α1-antitrypsin deficiency per se68 but currently the American 
Thoracic Society/European Respiratory Society guidelines 
do not recommend this procedure pending the emergence of 
further evidence.43 There are case reports of successful use 
of less invasive procedures including endobronchial valve 
placement69 though experience remains limited.
Lung transplantation is also an option for patients with 
end-stage emphysema. Because COPD often develops at an 
early age in α1-antitrypsin-deficient individuals, they tend to 
be good candidates. Alpha-1-antitrypsin deficiency accounted 
for 3.2% of lung transplants (and 10% of transplants for 
emphysema) in the International Society for Heart and Lung 
Transplantation Registry in 2009,70 with a 1-year survival 
rate of 86% and a 3-year survival of 69% for transplants 
performed between 2006–2010. These figures are comparable 
with the general COPD population, 84% of whom are alive 
at 1 year and 67% at 3 years posttransplant.
Alpha-1 antitrypsin replacement therapy: 
current practice
The concept of using purified human α1-antitrypsin as intrave-
nous replacement therapy was first described in 1981 by Gadek 
and colleagues who demonstrated normalization of serum 
α1-antitrypsin levels and establishment of anti-elastase activ-
ity within the lower respiratory tract with weekly infusions.21 
Alpha-1 antitrypsin replacement therapy was subsequently 
approved by the United States Food and Drug Administration 
(FDA) in 1987 based on the demonstration that normal serum 
levels could be achieved with regular treatment.71 It is also 
available in Canada and many European countries and replace-
ment therapy is recommended in the joint American Thoracic 
Society/European Thoracic Society statement on the manage-
ment of α1-antitrypsin deficiency.43 Many other countries 
including the UK, New Zealand, and Australia await proof of 
clinical benefit before licensing. It is not indicated in individuals 
who have partial α1-antitrypsin deficiency (MZ heterozygotes) 
and in α1-antitrypsin deficiency-associated liver disease.
Replacement therapy is given as weekly intravenous 
infusions at a dose of 60 mg/kg. This is based on evidence 
that with such dosing, trough α1-antitrypsin levels can be kept 
above the “protective” threshold of 80 mg/dL. This threshold 
is based on the observation that patients with heterozygous 
phenotypes whose levels of α1-antitrypsin exceed this level do 
not usually develop lung disease.71 Four options are available 
for replacement therapy in the US: Prolastin® (Talecris 
Biotherapeutics, Research Triangle Park, NC), Aralast®  
(Baxter Healthcare, Deerfield, IL), Zemaira® (CSL Behring, 
King of Prussia, PA), and Glassia® (Baxter, Deerfield, IL), 
with a fifth, Trypsone® (Grifols, Barcelona, Spain), available 
in Spain. All consist of purified human α1-antitrypsin. The 
individual characteristics of each have been thoroughly 
reviewed elsewhere72 but they all appear to be equally effective 
with subtle differences in storage, preparation, infusion rate, 
and cost. Glassia®, licensed in October 2009 by the FDA, 
is the only ready-to-use formulation but requires a slower 
infusion rate of 0.04 mL/kg/minute, half that of the other 
preparations. The cost of replacement is dependent on body Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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mass but may be upwards of US$100,000 per annum – and 
is a lifelong treatment.73
Intravenous α1-antitrypsin is generally considered to be 
well tolerated and safe. It is contraindicated in patients with 
IgA deficiency as purified protein may contain small amounts 
of IgA, prompting a severe hypersensitivity reaction. As it 
is purified from human plasma there is a theoretical risk 
of transmission of infectious agents including viruses and 
prions, but such transmission has never been reported. The 
commonest reported side effects from the original preparation 
(Prolastin®) are dizziness, fainting, and dyspnea.74
Alpha-1-antitrypsin replacement therapy: 
evidence of efficacy
Evidence of a biochemical effect of weekly intravenous 
antitrypsin was quick to emerge. Serum α1-antitrypsin levels 
can be maintained above the postulated protective level and 
anti-elastase activity can concurrently be detected in broncho-
alveolar lavage fluid.71 Infused α1-antitrypsin is functionally 
active and antibodies do not develop following repeated 
infusion.75 There are inherent difficulties in attempting to estab-
lish the clinical efficacy of  α1-antitrypsin replacement therapy. 
Though the gene frequency makes α1-antitrypsin deficiency 
as common as cystic fibrosis, the heterogeneous nature of the 
disease means that only around 5%–10% of patients have been 
diagnosed.76 This means that the pool of patients on whom to 
undertake trials is relatively small and inevitably results in the 
majority of evidence coming from larger observational stud-
ies rather than the few randomized controlled trials, each of 
which contains a small number of participants.77 Additionally, 
the evolution of emphysema is slow, meaning that protracted 
studies are necessary to show differences in lung function 
decline and mortality.78 Indeed, Schluchter et al estimated 
that to detect a 40% reduction in mortality in 5 years, 684 
α1-antitrypsin deficient individuals with an FEV1 of 35%–49% 
predicted would need to be recruited over a 2-year period.79 
Furthermore enthusiasm from pharmaceutical companies to 
fund such trials may be lacking with their products already 
freely available in many countries.
Non-randomized trials
It was not until 1997 that the first observational study 
with concurrent controls addressing clinical efficacy of 
α1-antitrypsin replacement therapy was published. Seersholm 
and colleagues demonstrated a significantly slower rate 
of FEV1 decline in a cohort of 198 German α1-antitrypsin 
deficient patients on replacement therapy when compared 
with 97 Danish controls, particularly in those with an FEV1 
of 31%–65% predicted.80 In 1998 the National Heart Lung 
and Blood Institute α1-antitrypsin deficiency registry study 
group reported on 927 patients enrolled in their registry. 
They showed no overall difference in lung function decline 
between treated and untreated groups. However there was a 
significant benefit of treatment seen in those with moderate 
impairment of lung function (FEV1 30%–64% predicted); 
conversely those with an FEV1 . 80% predicted had a faster 
annual decline in FEV1 whilst on treatment than untreated 
individuals (P = 0.09). They also reported overall mortality 
figures in favor of α1-antitrypsin replacement, though no 
  difference in those with an FEV1 . 50% predicted.81 Wencker 
et al took a different approach in 2001, comparing decline 
in lung function in 96 patients before and after initiation of 
augmentation therapy. These authors observed an overall 
benefit of treatment, but in contrast to previous observational 
studies, they demonstrated no significant difference in those 
with FEV1 in the range 30%–65%. The most significant 
benefit was seen in the small subgroup with mildly impaired 
(. 65% predicted at enrolment) but rapidly declining 
FEV1, with annual FEV1 loss reducing from 255.7 mL/year 
to 45.8 mL/year on augmentation therapy (P = 0.0016).82 
Recently Tonelli et al studied 164 individuals from the 
Alpha-1 Foundation DNA and Tissue Bank, finding a benefit 
of treatment in ex-smokers with an FEV1 of less than 50% 
predicted. It was again noted that those with better lung 
function (FEV1 . 60% predicted) did worse on augmentation 
therapy as measured by FEV1 decline.83 This finding may in 
part be explained by a tendency for those with good but rapidly 
declining lung function to be started on augmentation therapy. 
The authors of these observational studies all acknowledge 
the limitations of their findings. Treatment decisions were 
made by patients’ physicians and the baseline demographics 
between groups were unmatched; in particular the baseline 
FEV1 was lower in the treatment cohort in all studies.
Randomized controlled trials
Alpha-1-antitrypsin replacement therapy had been available 
in the United States for 12 years before the first of two 
randomized controlled trials (RCTs) assessing its efficacy 
was published. In 1999 Dirksen et al84 reported on a cohort of 
58 ex-smokers with severe plasma α1-antitrypsin deficiency 
and an FEV1 of 30%–80% predicted. The active group 
was treated with 250 mg/kg iv α1-antitrypsin at 4-weekly 
intervals for at least 3 years. This dose had previously been 
shown to provide protective serum α1-antitrypsin levels for 
an average of 25 days of the 28-day interval.85 The study’s 
primary outcome measure was FEV1; there was no statistically Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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significant difference between groups but a trend toward faster 
decline of FEV1 was seen in the treated group. In contrast the 
authors were able to demonstrate a trend towards slower loss 
of lung density (measured by computed tomography [CT]) in 
the treated group, albeit with substantial deterioration in both 
groups. The study was not designed to address mortality.
In 2009 the results of the “exacerbations and computed 
tomography scan as lung end-points” (EXACTLE trial),86 
which used CT-assessed lung density as its primary outcome 
measure, were published. Participants had severe α1-antitrypsin 
deficiency, were ex- or never smokers and members of the 
treatment group were given 60 mg/kg weekly iv α1-antitrypsin 
replacement (the accepted dosing regimen) for a minimum of 
2 years. The authors again reported loss of lung density in both 
groups with a difference of borderline significance in favor of 
the treatment group over the entire treatment period in one of 
four analysis methods. No difference was seen in lung function 
parameters or exacerbation rate between groups, though a 
post hoc analysis suggested that exacerbation severity may 
be milder in the treatment group. A third RCT which plans to 
address the question of mortality, albeit only as a secondary 
endpoint, is ongoing.87
A meta-analysis of some of the early trials comprising 
1509 patients concluded that FEV1 decline was slower 
in treated versus untreated individuals.80–82,84,88 This was 
particularly evident in those with an FEV1 of 30%–65% 
predicted, who experienced a 26% reduction in the rate of 
decline in FEV1 as a result of replacement therapy.89 The 
randomized trials were the subject of two meta-analyses 
that reached quite different conclusions. A Cochrane review 
concluded that a lack of evidence regarding mortality 
combined with conflicting evidence for treatment efficacy 
from FEV1 and CT data meant that replacement therapy 
cannot be recommended at present and that further studies 
should be large enough to detect an effect on mortality.22 A 
response from the expert community raised concerns over the 
methodology of this review, particularly regarding differences 
in drug and dosing regimens, and dropout rates between 
studies. The authors also questioned whether observational 
data should have been included in a meta-analysis of this 
rare condition.77
Stockley and colleagues re-analyzed the 1999 RCT data 
and, combined with the EXACTLE data, demonstrated a 
significant reduction in lung density decline in the treated 
versus untreated group (P = 0.006). They agreed that further 
studies are warranted, but that there is sufficient evidence of 
treatment efficacy that in future trials an iv placebo group is 
not ethically warranted.90
Exacerbations and airway inflammation
One study asking patients to self-report symptoms after 
initiation of replacement therapy found that 56 of 89 patients 
reported a definite decrease in exacerbation number from an 
average of 3–5 per year to 0–1 per year.91 Others have noted 
ongoing exacerbations despite treatment92 and the EXACTLE 
trial did not find a reduction in exacerbation frequency on 
treatment. Augmentation therapy does however seem to have 
an effect upon markers of airway inflammation. Stockley et al 
noted an increase in sputum α1-antitrypsin to the levels seen 
in nondeficient individuals with intravenous replacement; 
this was associated with a decrease in sputum LTB4 but there 
was no significant change in markers of neutrophil number 
and activation: IL-8 and myeloperoxidase (MPO). They 
suggest that this may reflect decreased LTB4 secretion by 
macrophages due to a reduction in uninhibited elastase.93
Table 2 summarizes the trial data discussed above. The 
very nature of observational studies along with their con-
flicting results must limit their role in confirming treatment 
efficacy. RCTs to date have been small scale. They suggest 
a lack of treatment benefit as measured by lung function, but 
raise the possibility of a positive impact on the rate of lung 
density loss as measured by CT, a parameter thought to be 
a more accurate measure of disease progression than lung 
function.94 The effect of augmentation therapy on mortality 
has not been adequately addressed. As outlined by Schluchter 
and colleagues79 the scale of trial required would be likely 
to require international collaboration. With disparate current 
clinical practice and a lack of agreement on the ethical design 
of future trials to assess disease progression, it seems this 
question will remain unanswered.
Assessing replacement therapy in the 
context of disease pathogenesis
Practical problems with clinical assessment of intravenous 
α1-antitrypsin replacement have been outlined above.   Putting 
this treatment in the context of disease pathogenesis may 
provide more understanding of the questionable   efficacy 
demonstrated to date. Weekly iv α1-antitrypsin provides 
protective levels of circulating protein as measured by a 
threshold over which individuals do not develop lung disease. 
However α1-antitrypsin is an acute phase protein with levels 
increasing by up to 130% in response to stress and peaking 
at up to 6 g/L;95 perhaps the ability to mount such a response 
may be of critical importance rather than the baseline level. 
Alpha-1-antitrypsin secretion may also be under the   control 
of growth hormone working synergistically with other 
  pituitary hormones, which leads to variable hepatic serum Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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and mRNA levels.96 Replacement therapy cannot address 
this; it can be envisaged that a patient would be particularly 
vulnerable shortly before the next infusion is due, especially 
the significant number of individuals who receive bi-weekly 
or monthly treatment.81 Based on knowledge of disease patho-
genesis it follows that α1-antitrypsin replacement therapy 
should address some of the drivers of lung disease: (i) it can 
effectively inhibit neutrophil elastase where the inefficient 
Z α1-antitrypsin monomers and inactive polymers would 
otherwise leave uninhibited elastase activity; (ii) the result-
ing lack of free elastase reduces LTB4 release from alveolar 
macrophages, thereby reducing the chemotactic signaling 
to neutrophils.93 Despite this, levels of MPO are unchanged 
in those on replacement suggesting that equal numbers of 
neutrophils are present (though they will have their elastase 
inhibited).
However replacement therapy will not affect (i) the 
  formation of Z α1-antitrypsin polymers that become lodged in 
the lung interstitium and act as neutrophil chemoattractants; 
(ii) intracellular Z α1-antitrypsin polymers in epithelial cells 
and alveolar macrophages that continue to induce stress 
signaling and release of pro-inflammatory cytokines.
We can postulate that a patient on augmentation therapy 
may have less tissue destruction as a result of better   regulation 
of neutrophil elastase activity, but will continue to have 
chronic inflammation in response to intrapulmonary polymers. 
In the small minority of patients who are α1-antitrypsinnull 
homozygotes then lung damage entirely reflects the absence 
Table 2 Studies of α1-antitrypsin replacement therapy
Author(s) Study type Primary (secondary) 
outcome measure(s)
Salient results
Non-randomized studies
Seersholm et al80 Observational study with 
concurrent controls
Fev1 decline – Slower FEV1 decline in treated group  
      Most marked benefit in those with FEV1 31%–65% 
predicted
NHLBi study81 Observational study with 
concurrent controls
Fev1 decline;  
Mortality
– No overall difference in Fev1 decline  
      Slower FEV1 decline in those with Fev1 30%–64% predicted  
Faster decline in those with Fev1 . 75% predicted 
– Decreased mortality in treated group
wencker et al82 Observational study of patients 
pre- and during treatment
Fev1 decline – Overall slower Fev1 decline on treatment  
    Most significant benefit in those with FEV1 . 65%  
    no significant difference in those with FEV1 30%–65%
Tonelli et al83 Observational study with 
concurrent controls
Fev1 decline  
(mortality)
–   Slower decline in treated group if FEV1, 50% predicted and 
ex-smoker. 
      Faster decline in treated group if Fev1 . 60%. 
– No difference in mortality
RCTs
Dirksen et al84 Double-blind placebo  
controlled RCT
Fev1/DLCO decline,  
(CT densitometry)
– No difference in Fev1 or DLCO  
–   Trend towards slower annual loss of lung density in treated 
group
Dirksen et al86 Double-blind placebo  
controlled RCT
CT densitometry  
(lung function,  
health status, exacerbations)
– Trend towards reduction in lung density loss in treated group 
– No difference in Fev1 or DLCO  
–   No difference in exacerbation rate but exacerbations less 
severe in treated group
Meta-analyses
Gøtzsche and 
Johansen22
Review of RCTs Mortality,  
Fev1 decline
–   Reduction in lung density loss in treated group over whole 
trial period 
– Trend towards faster Fev1  decline in treated group (P = 0.06)
Stockley et al90 integrated analysis of RCTs CT densitometry,  
Fev  1 decline
– Reduction in lung density loss in treated group (P = 0.006)  
– Trend towards faster Fev1 decline in treated group (P = 0.321)
Studies on exacerbations
Lieberman91 Patient survey exacerbation  
frequency
–   Reduction in exacerbation frequency from 3–5 per annum 
to 0–1 per annum following initiation of treatment
Stockley et al93 Clinical study using BAL  
from patients on α1-antitrypsin 
replacement
Sputum inflammatory  
markers
–   Sputum LTB4 significantly reduced following weekly  
60 mg/kg α1-antitrypsin replacement. 
– Non-significant reductions in IL-8 and MPO
Abbreviations: BAL, bronchoalveolar lavage fluid; DLCO, diffusing capacity of the lung for carbon monoxide; CT, computed tomography; Fev1, forced expiratory volume   
in 1 second; iL-8, interleukin 8; LTB4, leukotriene B4; MPO, myeloperoxidase; NHLBi, national heart lung and blood institute; RCTs, randomized controlled trials.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of neutrophil elastase inhibition. This group is most likely to 
benefit from replacement therapy. However in the majority of 
patients who have polymerogenic mutations it may be that the 
benefit of replacement therapy is attenuated by the ongoing 
inflammatory response to polymers.
Clinical and laboratory studies designed specifically to 
address this question would be of enormous value. A trial 
comparing treatment efficacy in individuals homozygous for 
null α1-antitrypsin alleles with those with polymerogenic 
alleles may shed light on the impact of α1-antitrypsin 
polymers in attenuating the beneficial effects of augmentation 
therapy. This would provide crucial information on the 
relative role of α1-antitrypsin polymers in the pathogenesis 
of emphysema. Additionally if small molecules that block 
α1-antitrypsin polymerization97 can be further developed, 
these can be tested in vivo to determine whether the absence 
of intrapulmonary polymers slows the rate of development 
of emphysema.
Conclusion
The current literature provides good evidence of the safety and 
biochemical effect of intravenous α1-antitrypsin replacement 
but there is no widely accepted proof that it affects disease 
progression or mortality. Further large scale RCTs would help 
clarify the impact of long-term intravenous α1-antitrypsin 
replacement on loss of lung density, which is emerging as 
an important surrogate marker of disease. Combined results 
from such trials may confirm CT densitometry as the best 
marker of disease severity and progression in α1-antitrypsin 
deficiency as well as adding to a body of evidence that could 
be used to determine any effect on mortality.
The evolving knowledge of the molecular basis of disease 
requires us to re-evaluate the utility of replacement therapy in 
individuals with α1-antitrypsin deficiency. A logical approach 
is to turn away from simply replacing deficient protein and 
toward tackling the key feature of this disease: the tendency 
of mutant α1-antitrypsin to polymerize.18 Strategies that result 
in the secretion of normally folded, functional protein would 
impact on both intracellular stress signaling and the systemic 
inflammation caused by polymers and in turn should prevent 
the development of both liver and lung disease, although 
whether this will become a reality remains to be seen.
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